Quark believes that intellectual property rights are essential to protect its technologies and products and to attract the investment required to bring a siRNA drug candidate to market.

Quark holds multi-layer intellectual property that protects its technological capabilities from target selection through siRNA design and preclinical validation to the clinic and enables us to develop therapeutic siRNA compounds for use in treating a plethora of human indications.

We have assembled a strong patent portfolio based on internally developed and licensed-in technologies, including BiFAR^TM gene discovery platform gene targets identified using BiFAR^TM , siRNA sequences and structures, , delivery modes and therapeutic indications. We own or control a portfolio of patents and patent applications to protect our technologies and products comprised of over 79 granted patents in the U.S., Europe and other countries, and approximately 140 patent applications in the U.S. and throughout the world.

We maintain a strong intellectual property position to cover 

• siRNA therapeutic candidates including thousands of sequences to hundreds of target genes; 
• siRNA drug candidates; 
• optimized siRNA drug design; 
• therapeutic use of siRNA to treat multiple indications;
• siRNA delivery modes to target cells/tissues/organs.

Quark strives to establish freedom-to-operate for each of its therapeutic candidates and methods of use for specific indications and believes its recently developed therapeutic siRNA compounds are unencumbered by third party IP in major commercial territories. Quark attempts to keep up-to-date with all developments in the siRNA intellectual property arena, taking into consideration inherent uncertainties in all third party IP analyses.